India Telmisartan Market Size, Share & Forecast 2026 | TechSci Research

MARKET INTELLIGENCE . CONSULTING

www.techsciresearch.com

INDIA TELMISARTAN MARKET

FORECAST & OPPORTUNITIES

FY2016 –FY2026

2

Scope of ReportProduct of Interest (POI): Telmisartan

Review Period

FY2016 – FY2019

Base Year

FY2020

Estimated Year

FY2021

Forecast Period

FY2022 – FY2026

Year Range

Telmisartan, sold under the brand name Micardis among others, is a medication used to treat high

blood pressure, heart failure, and diabetic kidney disease. It is a reasonable initial treatment for high

blood pressure.

Market Segmentation

COMPOSITION

• Single

• Combinational

REGION

• North

• South

• East

• West

• In-house

• Contract Manufacturing

Organizations

SOURCE

FORM

• Tablet

• Capsules

• Oral Solution

ROUTE OF

ADMINISTRATION

• Oral

• Intravenous

FORM

• Tablet

• Capsules

• Injection

• Others

DISTRIBUTION CHANNEL

• Online

• Offline

INDICATION

• Hypertension

• Cardiac Arrest

• Stroke

• Others

END USER

• Adult

• Pediatric

3© TechSci Research

Table of Contents

S. No. Contents Page No

1. Product Overview (Definition of product and major terminologies used in the report)

2.Research Methodology (Detailed description of the methodology used to conduct the research,Raw data backup, list of all secondary sources, List of respondents for primary surveys)

3. Impact of COVID-19 on India Telmisartan Market

4. Executive Summary

5. Manufacturing Telmisartan

5.1. Raw Material

5.2. Machinery

5.3. Manufacturing Methods

5.4. Contact Details of Machinery & Raw Material Supplies

6. Pharmacodynamic Overview of Telmisartan

6.1. Mechanism of Action

6.2. Absorption

6.3. Volume of Distribution

6.4. Protein Binding

6.5. Metabolism

6.6. Route of Elimination

6.7. Half-Life

6.8. Clearance

6.9. Toxicity

7. India Telmisartan Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value & Volume

7.2. Market Share & Forecast


Table of Contents


7.2.1. By Source (In-house v/s Contract Manufacturing Organizations)

7.2.2. By Composition (Single, Combinational)

7.2.3. By Form (Tablet, Capsule, Injection, Others)

7.2.4. By Route of Administration (Oral v/s Intravenous)

7.2.5. By Distribution Channel (Online v/s Offline)

7.2.6. By Indication (Hypertension, Cardiac Arrest, Stroke, Others)

7.2.7. By End User (Adult v/s Pediatric)

7.2.8. By Region (North, East, West, South)

7.2.9. By Company (FY2020)

7.3. Product Market Map

8. Market Dynamics (This chapter assesses the major demand drivers and restraints.)

8.1. Drivers

8.2. Challenges

9.Market Trends and Developments (This section captures recent trends pertaining tomanufacturing or consumption, market movements in terms of points of production andconsumption, advancements and development)

10. Policy & Regulatory Landscape

10.1. Custom Duty & Taxes

10.2. Government Subsidy & Benefits

10.3. Relevant Policies & Regulations (GMP, USFDA, WHO Certifications)

11. Import & Export Analysis

12. Pricing Analysis

13. India Economic Profile

14. Competitive Landscape


Table of Contents


14.1. Competition Outlook

14.2. Company Profiles (Top 10 Leading Companies)

14.2.1. Company Details

14.2.2. Product Plants & Capacity

14.2.3. Financials (If Available)

14.2.4. Captive Consumption vs Merchant Sale

14.2.5. Current & Future Plans

15.Strategic Recommendations (Based on the findings of the report strategic recommendations onhow to enter and expand market share)

16. About Us & Disclaimer

RESEARCH METHODOLOGY

7

Research Methodology

✓ Identifying Key Opinion

Leaders

✓ Questionnaire Design

✓ In-depth Interviews

Data Collection

Developing List of Respondents

Formulating Questionnaire

Market Profiling

Data Validation

Data Analysis

In-depth secondary

research was conducted

to determine top

players in the India

telmisartan market,

overall market size and

segmental market size.

In order to conduct

industry experts’

interviews, TechSci

formulated a

detailed discussion

guide.

List of industry

players and

industry specialists

was developed.

TechSci conducted

interviews with

industry experts and

industry players for

data collection and

verification.

Data obtained as

a result of

primary and

secondary

research was

validated through

rigorous

triangulation.

The data was scrutinized

using MS-Excel,

statistical tools and

internal proprietary

database to obtain

qualitative and

quantitative insights

about the India

telmisartan market.

Data

Collection

Data Filter

& AnalysisResearch &

Intelligence

Actionable

InsightsBusiness

Solution

Primary Research Desk Research Company Analysis

✓ Recent Developments

✓ Market Changing

Aspects/Dynamics

✓ Government Policies

✓ Conclusion

✓ Market Participants

✓ Key Strengths

✓ LinkedIn

✓ TechSci Internal

Database

✓ Factiva

✓ Hoovers

Paid Sources

✓ Company Websites

✓ Company Annual

Reports

✓ White Paper Study

✓ Financial Reports

✓ Investor

Presentations

✓ Regulatory Body

✓ Associations, etc.

Secondary Research

Primary Research

8


Baseline Methodology

Our dedicated team of industry experts has monitored and analyzed various aspects of India telmisartan market. The team has analyzed the outlook of

various segments of this market, while considering the major influencing factors such as surging population with cardiovascular and heart associated

disorders in India. The study includes market forecasting, which would enable our clients to take better decisions while planning their strategy to achieve

sustainability in India telmisartan market.

Methodology Followed for Calculation of Market Size:

• Market Size By Value & Volume : Market size, in terms of value, for the year FY2020 was calculated based on information collected through

exhaustive secondary research and primary surveys, with various key opinion leaders/stakeholders, such as manufacturers, suppliers, channel partners,

end users, industry experts, and other industry participants.

• The team interviewed more than 40 – 50 manufacturers, suppliers, 180 – 200 end users, and 15 – 20 industry experts and other value & volume chain

stakeholders in the India telmisartan market to obtain the overall market size from FY2016 to FY2020, which was validated by the Delphi technique.

Taking standard deviation into consideration, the market size was averaged out, to arrive at the market size data during FY2016-FY2020.

• Respondents were asked about the current and future market growth rates, market shares by source, by composition, by form, by route of

administration, by distribution channel, by indication, by end user, by region and by company. Removing the outlier responses, the geometric mean of

growth estimates and supplier wise revenue shares generated across various segments were considered, to arrive at the final revenue shares. Revenue

shares generated across various segments were further triangulated from other stakeholders.

9


Methodology Followed for Calculation of Market Shares:

Market shares by source, by composition, by form, by route of administration, by distribution channel, by indication, by end user, by region and by

company were calculated based on the responses received through primary surveys with industry experts, in which the respondents were asked about

the market shares or revenue generated from various segments of telmisartan market. The final shares were calculated by taking the geometric mean

of the responses gathered from key opinion leaders after eliminating the outliers.

Methodology Followed for Forecasting:

• TechSci Research performed periodical checks on data collected through the surveys with logic checks and analyzed the survey results in

SPSS/Tableau Software.

• Data triangulation techniques were applied to fill the gaps and to present a more meaningful picture of the market. To forecast India telmisartan

market, TechSci Research used various forecast techniques such as:

✓ Moving Average

✓ Time Series Analysis

✓ Regression Analysis

✓ Econometric and Judgmental Analysis

10


TechSci Research used its own forecast tool, which is based on the growth of various allied industries in respective regions. TechSci Research also used

the impact analysis during short, medium and long term period to estimate the demand and to reach accurate market numbers. It should be noted that

the figures compiled are only for the organized market including market share data.

Partial List of Companies Interviewed Key Secondary Sources

▪ Boehringer Ingelheim India Pvt. Ltd.

▪ Novartis India Ltd.

▪ Venus Remedies Ltd.

▪ Candomed Pharmaceuticals India Pvt. Ltd

▪ Torrent Pharmaceuticals Ltd.

▪ Cipla Limited (Exelan Pharmaceuticals)

▪ Astellas Pharma India Pvt. Ltd.

▪ Lupin Laboratories Ltd.

▪ 14.1.9. Mylan Laboratories Ltd.

▪ Glenmark Pharmaceuticals Ltd.

▪ World Bank

▪ TechSci Research Proprietary Database & Knowledge

Repository

▪ Company Annual Reports

▪ Industry Magazines

▪ Industry Reports

▪ News Dailies

▪ Credible Paid Databases

11

Industry Brief

According to TechSci Research report, “India Telmisartan Market By Indication (Hypertension, Cardiac Arrest, Stroke, Others), By Composition

(Single, Combinational), By Form (Tablet, Capsule, Injection, Others), By Route of Administration (Oral v/s Intravenous), By Source (In-house v/s

Contract Manufacturing Organizations), By Distribution Channel (Online v/s Offline), By End User (Adult v/s Paediatric), By Company, By Region,

Forecast & Opportunities, FY2026”, the India telmisartan market is expected to grow at a steady rate during the forecast period for the treatment

of essential hypertension. In addition to this, rising demand for developing antihypertensive drugs is expected to fuel the market growth through

FY2026. However, side-effects associated with drug consumption such as upper respiratory tract infections, diarrhea, back pain, kidney

problems, low blood pressure, and angioedema can restrict the market growth over the next few years. Moreover, in certain cases use of this

drug in pregnancy may harm the baby. This can further reduce the usage and application of the drug thereby hindering the market growth during

the forecast period.

The India telmisartan market is segmented based on indication, composition, form, route of administration, source, distribution channel, end user,

company, and region. Based on indication, the market can be fragmented into hypertension, cardiac arrest, stroke, others. The hypertension

segment is expected to dominate the market in the forthcoming years on account of rising prevalence of high blood pressure among the

population. Based on source, the market can be categorized into in-house v/s contract manufacturing organizations. The in-house segment

dominated the market until 2017 as most of the leading companies focus on in house production. Contract manufacturing organizations segment

is expected to witness significant growth in the market as it saves cost and maximize profits. Besides, high growth in number of contract

manufacturers is further contributing to its fast growing CAGR. In terms of form, the market is split into tablet, capsule, injection, others. Among

them, the capsule segment is anticipated to dominate the market in the next 5 years which is attributable to the fact that they are easy to use and

readily available. Also, the tablet segment is expected to register high growth during then forecast years on account of their properties such as

high stability of tablets and longer shelf life.

Astellas Pharma India Pvt. Ltd., Boehringer Ingelheim India Pvt. Ltd., Novartis India Ltd., Venus Remedies Ltd., Candomed Pharmaceuticals

India Pvt. Ltd, Torrent Pharmaceuticals Ltd., Cipla Limited (Exelan Pharmaceuticals), Lupin Laboratories Ltd., Mylan Laboratories Ltd., Glenmark

Pharmaceuticals Ltd., Astellas Pharma India Pvt. Ltd. and others are some of the leading players operating in India telmisartan market.

Companies operating in the market are using Go-To-Market strategies such as product launches, mergers, and collaborations to boost their

share and increase their geographic reach. For instance, In 2017, Zydus Cadila which is one of the leading pharmaceutical company in the

market received permission to sell its version of temisartan and hydrocholothiazide tablets and the drug was brought into the market in three

different dosages, which contributed in strengthening their market share.

“India Telmisartan market is expected to witness growth during the forecast period as it is used to treat patients with high blood pressure and

thereby aids to prevent strokes, heart attacks, and other related conditions in an individual. Telmisartan medication is also very effective in

treating diabetic kidney disease. This is further expected to create lucrative opportunities for the market growth of India Telmisartan market over

the next five years.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based India management consulting firm.

12

Sample Data - Snapshot

5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00

10.00 20.00 30.00 40.00 50.00 60.00 70.00 80.00 90.00 100.00 110.00

FY2016 FY2020 FY2021E FY2026F

By Value (USD Million)

By Volume (Million Units)

India Telmisartan Market Size, By Value (USD Million) & Volume (Million Units), FY2016–FY2026F

CAGR By Value & Volume

XX%

CAGR By Value & Volume

YY%

India Telmisartan Market Share, By Source, By Value, 2015–2025F

60%60%60%60%60%60%60%60%60%60%60%

40%40%40%40%40%40%40%40%40%40%40%

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021E

FY2022F

FY2023F

FY2024F

FY2025F

FY2026F

In-house Contract Manufacturing Organizations

India Telmisartan Market Share, By Indication, By Value, 2015–2025F

25%25%25%25%25%25%25%25%25%25%25%

25%25%25%25%25%25%25%25%25%25%25%

25%25%25%25%25%25%25%25%25%25%25%

25%25%25%25%25%25%25%25%25%25%25%

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021E

FY2022F

FY2023F

FY2024F

FY2025F

FY2026F

Hypertension Cardiac Arrest Stroke Others

13

Report Ordering

License Type Price

Electronic Access - Single User License $2950

Electronic Access - Multi-User License $3750

Custom Research License $7500

Report Price

To View Sample OR Purchase Report

Report Name: INDIA TELMISARTAN MARKET

FORECAST & OPPORTUNITIES

FY2016 –FY2026

https://www.techsciresearch.com/report/india-telmisartan-market/5150.html

About Us & Disclaimer

TechSci Research is a global market research and consulting company with offices in the US, UK and India. TechSci Research provides market research reports in number of areas

to organizations. The company uses innovative business models that focus on improving productivity, while ensuring creation of high-quality reports. The proprietary forecasting

models use various analyses of both industry-specific and macroeconomic variables on a state-by-state basis to produce a unique ‘bottom-up’ model of a country, regional and

global industry prospects. Combined with the detailed analysis of company activity and industry trends, the result is a uniquely rich evaluation of the opportunities available in the

market.

Related Reports

• India Streptomycin Market By Source (In-house v/s Contract Manufacturing Organizations), By Form (Tablet, Capsule and Injection), By Route of

Administration (Oral v/s Intravenous), By Type of Manufacturing Process (Natural, Synthetic and Semi-synthetic), By Distribution Channel (Online v/s

Offline), By Application (Tuberculosis, meningitis, throat Infection, endocarditis, brucellosis, plague, tularemia, rat bite fever and Others), By End User

(Adult v/s Paediatric), By Company, By Region, Forecast & Opportunities, FY2026

• India Potassium Clavulanate Market By Composition (Single, Combinational), By Route of Administration (Oral v/s Intravenous), By Form (Tablet,

Capsule, Syrup, Injection), By Distribution Channel (Online v/s Offline), By Source (In-house v/s Contract Manufacturing Organizations), By

Application (Respiratory Tract Infections, Skin Infections, UTI, Otitis media, Gynaecological infections, Bone and Joint Infections and Others), By End

User (Adult v/s Pediatric), By Company, By Region, Forecast & Opportunities, FY2026

The contents of this report are based on information generally available to the public from sources believed to be reliable. No representation is made that it is timely, accurate or

complete. TechSci Research has taken due care and caution in compilation of data as this has been obtained from various sources including which it considers reliable and first hand.

However, TechSci Research does not guarantee the accuracy, adequacy or completeness of any information and it is not responsible for any errors or omissions or for the results

obtained from the use of such information and especially states that it has no financial liability whatsoever to the subscribers / users of this report. The information herein, together

with all estimates and forecasts, can change without notice. All the figures provided in this document are indicative of relative market size and are strictly for client’s internal

consumption. Usage of the same for purpose other than internal will require prior approval of TechSci Research.

TechSci Research – North America708 Third Avenue, Manhattan,

New York, United States

Tel: +1- 646- 360- 1656

Email: [email protected]


Disclaimer

TechSci Research – Europe54, Old brook, Bretton,

Peterborough,

United Kingdom



TechSci Research – Asia-PacificB – 44, Sector – 57, Noida, National Capital

Region, U.P. - India

Tel: +91-120-4523900



India Telmisartan Market Size, Share & Forecast 2026 | TechSci Research

Health & Medicine

Transcript of India Telmisartan Market Size, Share & Forecast 2026 | TechSci Research